GlassScriptPhysician profile
Sherri Crespin
NPI 1326188301
$5,385.39
in general payments reported to CMS, 2019-2025
19 companies · $79.28 in 2025
The $79.28 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,621 · 2022: $1,419 · 2023: $1,416 · 2024: $850 · 2025: $79.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400 · Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
| Food and Beverage | $945.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,200.00 | 2021-2023 | |
| Abbvie INC. | $336.89 | 2023-2024 | |
| Galderma Laboratories, L.P. | $179.20 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $91.33 | 2024 | Rexulti |
| Almatica Pharma LLC | $74.10 | 2024-2025 | Loreev Xr |
| Alkermes, INC. | $68.87 | 2024 | Lybalvi, Aristada |
| Corium, LLC | $67.65 | 2024 | Azstarys |
| Lundbeck LLC | $64.99 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $56.17 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $39.15 | 2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $34.37 | 2024 | |
| Redhill Biopharma INC. | $27.71 | 2021 | |
| Vanda Pharmaceuticals INC. | $25.50 | 2025 | Fanapt |
| Bausch Health US, LLC | $22.91 | 2024 | Aplenzin |
| Neurocrine Biosciences, INC. | $22.08 | 2024 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.79 | 2024 | Caplyta |
| Csl Behring | $20.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.72 | 2024 | |
| Optinose US, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherri Crespin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.